B2M and colorectal carcinoma: For example, none of the gene mutation rates of IFNGR1 (1.7%), IFNGR2 (1.5%), JAK1 (4%), JAK2 (4%), STAT1 (4%), HLA-A (3%), HLA-B (5%), HLA-C (3%), or B2M (6%) are found in excess of 6% in patients with CRC based on 526 samples data from TCGA datasets [34].